Iron overload contributes to increased transplant-related mortality, and serum ferritin is typically used to detect iron overload. Other iron parameters have received limited attention. We studied serum ferritin, transferrin, transferrin saturation, iron, soluble transferrin receptor (sTfR) and C-reactive protein (CRP) levels in 230 consecutive patients undergoing myeloablative allo-SCT. All iron parameters were significantly associated with survival. When analyzed individually, both sTfR and transferrin saturation were superior in prognostic power to ferritin (areas under the curve in receiver operating characteristic analysis: 0.670, 0.715, and 0.657, respectively). A combination of ferritin and transferrin saturation had the highest prognostic power: Patients with ferritin below the 30th percentile (o802 ng/mL) showed excellent survival (70 ± 6% at 5 years), while transferrin saturation above the 80th percentile (X69%) pointed to a high risk of transplant failure (5-year survival 5 ± 5%). The remaining patients showed an intermediate outcome (5-year survival 52±5%). The prognostic impact of iron parameters was independent of other factors such as stage, conditioning regimen and CRP level, and operated similarly across diseases. Iron overload strongly influenced the outcome of allo-SCT. Low pre-transplant ferritin levels indicate a population at low risk, high transferrin saturations and a subgroup of patients with very poor outcome.
Introduction
Since the introduction of hematopoietic SCT (HSCT) as a curative treatment for malignant and nonmalignant diseases, efforts have been made to improve outcome by ensuring that patients are in optimal condition pretransplant. Most patients requiring allogeneic transplantation have undergone red blood cell transfusion before transplantation, and iron overload is therefore frequent in this population. 1, 2 Iron overload is associated with free radicals and tissue damage, and may therefore increase the risk of post-transplant morbidity and mortality. [3] [4] [5] Serum ferritin levels are routinely assessed as markers of iron overload and have been found to act as powerful predictors of transplant outcome. However, serum ferritin also operates as an acute-phase protein, limiting its usefulness in the assessment of iron content in patients with such a condition. It is unclear whether elevated ferritin as a predictor of poor transplant outcome acts only as a marker for iron overload, or whether ferritin also operates as a surrogate marker for patients with inflammatory conditions (such as infections) that may convey an ironindependent risk for transplant-related morbidity and mortality. 6 Other iron-related parameters such as iron, serum transferrin and transferrin saturation share similar limitations. 7 Assessment of serum soluble transferrin receptor (sTfR) was recently introduced, as this protein correlates inversely with total body iron stores and is not affected by inflammatory processes. 8 The predictive impact of iron parameters other than ferritin on outcome after SCT has not been assessed so far.
The aim of this retrospective study in 230 consecutive patients undergoing T-cell-replete, myeloablative allogeneic HSCT was to correlate serum iron parameters (iron, transferrin, transferrin saturation, ferritin, sTfR) with each other and to CRP as a marker of inflammatory states. All of these parameters were further analyzed regarding their impact on transplant outcome (OS, relapse and TRM).
Patients and methods

Transplant procedure
We analyzed 230 consecutive patients undergoing myeloablative allogeneic transplantation at our institution. C-reactive protein levels and serum iron parameters were assessed 2-5 days before start of conditioning. Patients were categorized into groups with low or high serum ferritin, sTfR, iron, transferrin, transferrin saturation and C-reactive protein levels based on values below or above the respective medians. In patients who had exclusively received transfusions at our center and for whom a complete transfusion history was available (n ¼ 65), pretransplant iron parameters were additionally correlated with the number of pre-transplant red blood cell transfusions administered.
Underlying diseases were non-malignant disorders (n ¼ 7), ALL (n ¼ 43), AML (n ¼ 94), myelodysplastic syndrome/ myeloproliferative neoplasms (MDS/MPN, n ¼ 49), and lymphoma and multiple myeloma (n ¼ 37). Disease stage was defined according to previously published classifications. 9 Conditioning consisted of CY, TBI þ /À etoposide, or CY and BU in patients with acute leukemia, myelodysplastic syndrome or myeloproliferative neoplasm. Patients with lymphoma were conditioned with BEAM, fludarabine and TBI. All patients gave written informed consent to the transplant procedure and to having their data analyzed.
GVHD prophylaxis was with CsA þ mycophenolate mofetil in patients with lymphoma, and with CsA þ MTX in all others. More patient and transplant characteristics are summarized in Table 1 .
Statistics
Pre-transplant patient characteristics were compared by Pearson's chi-square or Fisher's exact test for categorical variables and Mann-Whitney's U-test for continuous variables. The correlations between serum iron parameters and C-reactive protein were assessed by Spearman's rank test. The impact of pre-transplant variables on transplant outcome was determined by calculating Kaplan-Meier estimates of OS, and cumulative incidences of disease relapse and TRM. Disease relapse and TRM were considered as competing risks and analyzed accordingly. Patients were grouped into those with high or low (above or below median) serum ferritin, sTfR, transferrin, transferrin saturation, iron and C-reactive protein levels. The impact of categorical variables on transplant outcome was assessed by log-rank and Gray's test, respectively. Predictors of transplant outcome were further assessed in univariable and multivariable Cox models into which variables were entered in a stepwise forward manner using a P-value cutoff of 0.20. Receiver operating characteristic (ROC) curves of censored survival data were calculated in R 2.10.1 (http://www.cran.r-project.org) using the survivalROC package, and used to compare the predictive power of different pre-transplant variables. Generalized linear models were used to assess the correlation between diagnosis, number of pre-transplant transfusions and pre-transplant ferritin levels. All comparisons were two-sided and P-values o0.05 were considered significant.
Results
Median pre-transplant serum levels were: ferritin 1342 ng/mL (range 7-7260, normal range 10-200); transferrin 1.9 g/L (range 0.8-3.5, normal range 2.0-3.6); transferrin saturation 36% (range 4-106%, normal range 16-45); iron 18 mmol/L (range 3-52, normal range 10-32); sTfR 3.2 mg/L (range 0.3-73, normal range 2.2-4.5); and CRP 9.3 mg/L (range 0.5-500, normal range o10). In contrast to the clear association in non-hematological patients, no statistically significant correlations were found between CRP levels and concentrations of serum ferritin (P ¼ 0.16), transferrin saturation (P ¼ 0.06) and serum iron (P ¼ 0.43) in our patient group. Weak, but statistically significant inverse correlations were found between CRP and levels of transferrin and sTfR (r ¼ À0.19 and À0.18, P ¼ 0.003 and 0.007, respectively, Table 2 ). All iron parameters analyzed showed highly significant correlations with the number of red blood cell transfusions administered pre-transplant (median 18, range 0-97). Finally-with the exception of the iron/transferrin combination-all iron parameters were highly significantly associated with each other when analyzed pairwise (Table 2) .
Iron parameters were associated with underlying diagnosis, with higher-than-median ferritin levels seen most frequently in patients with AML (65%) and ALL (56%), and less frequently in patients with lymphoma/myeloma (27%) and MDS/MPN (33%, P-value overall o0.001). High ferritin levels were slightly more frequent in female than in male patients (57 vs 45%, P ¼ 0.06), but were not associated with increasing age or more advanced disease; iron overload did not increase with longer interval from diagnosis to transplant (Table 1) . When number of transfusions was taken into account, differences between different diseases almost completely disappeared (data not shown), indicating that the higher number of pre-transplant transfusions was responsible for the elevated incidence of iron overload in patients with acute leukemia. When the impact of iron parameters on OS was analyzed, we found that 5-year survival rates were significantly affected by all iron parameters analyzed. When patients were grouped into those with levels below or above median, survival rates were (in descending order of predictive power): 64 ± 5% vs 32 ± 5% (likelihood ratio (LR) 23.2, Po10
À5
) for transferrin saturation; 34 ± 5 vs 65±5% (LR 20.2, Po10   À5 ) for sTfR; 61±5 vs 39 ± 5% (LR 13.1, P ¼ 0.0003) for ferritin; 38 ± 5 vs 59 ± 5% for transferrin (LR 10.6, P ¼ 0.001); and 58 ± 5 vs 39±5% (LR 8.1, P ¼ 0.005) for iron. Serum CRP levels were only borderline statistically significant predictors of OS (57 ± 5 vs 43 ± 5%, LR 3.7, P ¼ 0.05). Survival curves for all parameters are shown in Figure 1 . Ferritin, transferrin saturation and sTfR were chosen as the most significant predictors and further analyzed.
To compare the predictive power of ferritin, transferrin saturation and sTfR levels across different cutoffs, we assessed the sensitivity and specificity of these parameters using ROC curves. These confirmed transferrin saturation as the marker with highest sensitivity and specificity across a wide range of levels (area under the curve for transferrin saturation 0.715, sTfR 0.670 and ferritin 0.657, Figure 2a) . The shape of the ROC curve pointed to particularly good discriminatory power of transferrin saturation in values higher than median (lower left of curve); in contrast, ferritin was prognostically superior in the range below median values (upper right of curve), suggesting that a combination of these two markers might be particularly useful.
To define optimal cut-off points, we categorized patients into deciles (10-percent-intervals), and each cut-off was then added as a final variable to a Cox model, comparing the increase in likelihood ratio. Maximum increases occurred at the 30th percentile for ferritin (corresponding to 802 ng/mL) and at the 80th percentile for transferrin saturation (corresponding to 69% saturation). On stratifying patients according to both parameters, ferritin and transferrin saturation provided powerful prognostic information: a pre-transplant ferritin below the 30th percentile identified a group of patients with excellent transplant outcome (N ¼ 67, 5-year OS 70 ± 6%), whereas a transferrin saturation above the 80th percentile (X69%) was specific for patients with a high risk of early post-transplant Low ferritin: 61 ± 5% Low sTfR: 34 ± 5% High sTfR: 65 ± 5% P = 0.0003 P <10e-5
Low Tf-Sat: 64 ± 5% High Tf-Sat: 32 ± 5% P<10e-5
High ferritin: 39 ± 5% P =0.001 P = 0.005
High Tf: 59 ± 5%
Low Tf: 38 ± 5% Low iron: 58 ± 5% High iron: 39 ± 5% P =0.05
Low CRP: 57 ± 5% High CRP: 43 ± 5%
Years after transplantation Figure 3b) . In Cox models adjusted for disease, stage, graft source and pre-transplant CRP, pre-transplant iron retained independent statistical significance (hazard ratio (HR) in the low-risk group (ferritin o802 ng/mL) 1.00; HR in the intermediate-risk group (ferritin 4802 ng/mL and transferrin saturation o69%) 2.08, 95% CI 1.11-3.88, P ¼ 0.02; HR in the high-risk group (transferring saturation X69%) 3.65, 95% CI 1.89-7.08, Po0.001). As prevalence of iron overload differed widely between the diseases analyzed in this cohort, we performed subgroup analyses in patients stratified by disease. Adjusted survival curves of patients transplanted for ALL, AML, MDS/MPN and lymphoma/myeloma suggested that iron overload had a similar impact on transplant outcome in all diseases analyzed ( Figure 3) . Finally, we aimed to assess whether the strong impact of iron parameters on transplant outcome was derived mainly from an influence on disease relapse or on TRM. Surprisingly, ROC analysis revealed that ferritin, sTfR and transferrin saturation predicted TRM with similar reliability (AUC 0.607, 0.593 and 0.627, respectively). In contrast, the predictive power of iron parameters was superior for relapse and differences between the iron parameters analyzed were more prominent, with AUCs of 0.671, 0.714 and 0.739 for ferritin, sTfR and transferrin saturation, respectively.
Discussion
Our analysis produced several interesting findings. We confirmed the predictive power of serum ferritin levels for survival after allogeneic HSCT. Furthermore, we showed that soluble transferrin receptor-a marker most often used to detect iron deficiency-has a similar (or even slightly superior) predictive power. Previous data demonstrating the value of sTfR as a marker for iron overload are scarce, 10 but both our survival data and the clear negative correlation of sTfR with ferritin and transferrin saturation suggest that low sTfR levels are a useful marker of iron overload in this setting. This is further evidenced by the negative correlation of sTfR levels with the number of transfusions administered before transplantation.
The comparable predictive power of sTfR and ferritin suggests that the association of ferritin with transplant outcome indeed reflects its correlation with iron stores and not its role as an acute-phase protein. This finding is underlined by the fact that-in contrast to patients who have not received large numbers of transfusions 11 -in the current cohort CRP levels (as a sensitive marker of acutephase reactions) were not significantly associated with serum ferritin levels. Transferrin saturation proved to be an even more powerful predictor of survival than both ferritin and sTfR.
As previously described, iron parameters indicative of iron overload were associated with a significantly increased risk of TRM. 12, 13 The mechanism leading to excess TRM rates is currently unknown: we did not find an increase in GVHD in patients with iron overload (data not shown), a finding that confirms previous studies. Cytoreductive chemotherapy has been shown to release quantities of iron into serum that cannot be absorbed by transferrin, leading to generation of non-transferrin-bound iron (NTBI), which in turn produces hydroxyl radicals capable of causing cellular damage.
14 NTBI was predominantly demonstrated in patients with elevated pre-transplant transferrin saturation, and might be partly responsible for the increased TRM in patients with more severe iron overload. In this study, NTBI was not studied directly, and we can therefore only speculate that the superiority of transferrin saturation over ferritin as prognostic marker might be due to the closer correlation of the former with NTBI.
As a novel finding, we show that iron overload-as assessed by elevated ferritin, low sTfR levels and elevated transferrin saturation-is significantly associated with an increased risk of relapse. The reason for this association is unclear. Patients with advanced disease stage or those with a long interval between diagnosis and transplant did not show increased iron overload. Recent data in patients with myelodysplastic syndrome suggest an elevated risk of transformation to acute leukemia in patients with iron overload. 15 An increase of reactive oxygen species associated with NTBI, in turn inducing genomic instability in hematopoietic progenitors, has been postulated. A similar mechanism might also operate after allogeneic HSCT.
A clear association of iron overload with underlying disease was found in this study (highest in acute leukemia, lowest in MDS/MPN and in lymphoma/myeloma). However, these differences were virtually abrogated if the number of previously administered transfusions was taken into account. Additionally, the prognostic significance of iron overload was nearly identical if patients were stratified by disease, arguing against an effect related to the specific abnormalities in iron metabolism frequently found in myeloid malignancies. Despite this, the limitation remains that disease type, stage, donor type, conditioning and GVHD prophylaxis were heterogeneous in this cohort, which may limit the interpretation of results.
In conclusion, we show that iron overload has a widely varying prevalence in different disease categories; that serum ferritin is a powerful predictor of survival after allogeneic HSCT; that the predictive power is derived from its association with iron overload rather than with acute inflammation; that inferior survival in patients with iron overload is derived from an increase in both TRM and relapse; that sTfR and transferrin saturation have superior prognostic value when compared with ferritin; and that, for optimal discriminatory power, serum ferritin measurement may be combined with assessment of the transferrin saturation.
